Fig 1.
Scheme of untargeted metabolomics approach (CVR = cardiovascular risk), 4 CVD metabolites out of 36 were searched explicitly in the data.
Table 1.
Clinical characteristics of study population, presented in mean (± SD) for each sampling point: PRE (before surgery), POST (1–2 weeks after surgery), FU (one year after surgery) including p-values from paired t-tests.
Fig 2.
Multidimensional scaling plots from supervised Random Forests of initial 923 metabolic features show distinct clustering of samples taken before (PRE) and after the surgery for both points in time (POST, FU).
Fig 3.
Multidimensional scaling plot of unsupervised Random Forests using 177 selected metabolic features from all three sampling points.
Fig 4.
Boxplots of peak-AUC metabolites related to CVR for three different sampling points.
Table 2.
Unidirectional trends of changes in the intensities (peak-AUC) of identified metabolites before and after bariatric surgery, metabolites in bold have previously have been associated with CVR.
Table 3.
Bidirectional trends of changes in the intensities (peak-AUC) of identified metabolites before and after bariatric surgery, metabolites in bold have previously been associated with CVR.
Fig 5.
Metabolites showing a significant decline (FU/PRE) in diabetes remission (R) patients compared to non-remission (N-R).
Above: Metabolite changes over time, below: different metabolite levels for diabetes remission (R), non-remission (N-R) and non-diabetes patients (N-DM)